Phenyl Urea Derivatives Selective FPR1 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases lack selective modulation of FPR1 and FPR2 receptors, which are critical for regulating inflammatory responses and healing processes, leading to inadequate management of inflammatory conditions.
Innovation Solution
Development of phenyl urea derivatives that selectively modulate FPR1 relative to FPR2, acting as receptor agonists, antagonists, or partial agonists to treat disorders associated with FPR modulation, including inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are used, then inflammatory conditions can be managed, but selective modulation of FPR1 and FPR2 receptors is lacking, leading to inadequate management
Solution Approach 1:
The patent segments the FPR receptor family into two distinct targets: FPR1 and FPR2. By designing compounds that can selectively modulate each receptor type independently, the invention enables differentiated therapeutic approaches for inflammatory diseases, allowing clinicians to target specific pathological mechanisms through FPR1 or FPR2 modulation as needed
Solution Approach 2:
The patent employs parameter changes by developing compounds with varying selectivity profiles for FPR1 and FPR2. By adjusting molecular structure parameters of the phenyl urea derivatives, the invention creates a series of compounds with different degrees of selectivity, enabling optimization of therapeutic efficacy while minimizing off-target effects
2Adaptability or versatility
If FPR1 and FPR2 are modulated without selectivity, then broad anti-inflammatory effects may be achieved, but inadequate management of specific inflammatory conditions results
Solution Approach 1:
The patent introduces dynamic selectivity by designing compounds that can preferentially bind to either FPR1 or FPR2 based on specific inflammatory conditions. The phenyl urea derivatives exhibit adaptable binding characteristics that can be optimized for different disease states, allowing the same compound class to address diverse inflammatory pathologies with appropriate selectivity
Data Source
AI summary
The present invention relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as tools or as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.